FACT: There is insufficient public information available to...

FACT: There is insufficient public information available to enable the determination / statement being made by him but hey don’t take my word for it, here are the links to the trials / publicly available information


I welcome you to put forward a hypothesis to support the comparison he claims to have made of all three indications from his ‘research’ ? For example;


What dose limits were reached in all three trials when they were ‘compared’ by antibotter in relation to toxicity, safety etc ?


It’s easy to make bold statements but I prefer same to be substantiated with facts / data and in this case it cannot be done from the publicly available information - just sayin’



Enjoy your weekend !


https://clinicaltrials.gov/ct2/show/NCT03217838?term=NCT03217838&draw=2&rank=1

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.




https://clinicaltrials.gov/ct2/show/record/NCT03218683?term=NCT03218683&draw=2&rank=1

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies



https://clinicaltrials.gov/ct2/show/NCT04865419?term=Azd0466&draw=2&rank=1
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies